{"schema_version":"secwatch.filing_event.v1","accession":"0001326110-26-000077","form_type":"8-K","ticker":"IBRX","cik":"0001326110","company_name":"ImmunityBio, Inc.","filed_at":"2026-08-04T11:36:13+00:00","discovered_at":"2026-08-04T11:40:07.290953+00:00","generated_at":"2026-08-04T11:40:33.667860+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"ImmunityBio Q2 net product revenue $50.7M, up 92% YoY; eighth consecutive quarter of growth","bullets":["Net product revenue $50.7M in Q2 2026, up 92% YoY and 15% sequentially; first-half revenue $94.8M, up 121% YoY.","Cash and marketable securities $357.4M as of June 30, 2026; adjusted net loss improved to $81.0M from $89.9M YoY.","FDA accepted sBLA for ANKTIVA plus BCG in BCG-unresponsive NMIBC with papillary disease; PDUFA Jan 6, 2027.","UAE granted broadest marketing authorization for ANKTIVA across BCG-unresponsive NMIBC and metastatic NSCLC.","Exclusive development and supply agreement with Japan BCG Laboratory for intravesical Tokyo-172 BCG in NMIBC."],"urls":{"canonical":"https://secwatch.observer/filing/0001326110-26-000077","json":"https://secwatch.observer/filing/0001326110-26-000077.json","markdown":"https://secwatch.observer/filing/0001326110-26-000077.md","text":"https://secwatch.observer/filing/0001326110-26-000077.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000077/0001326110-26-000077-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000077/ibrx-20260804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T11:40:33.667860+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}